Milestone Pharmaceuticals Inc. announced that the PDUFA date for its nasal spray CARDAMYST™ (etripamil) for treating Paroxysmal Supraventricular Tachycardia (PSVT) has been set for March 27 ...

Milestone announced further details on its in-person and virtual Commercial Launch Plan investor event to take place in New York on Tuesday, ...

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for ...

The nasal spray, also known as etripamil, is currently under FDA review for a heart condition known as paroxysmal ...

PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in ...

Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops ...

Milestone’s New Drug Application (NDA) for CARDAMYST™ (etripamil) nasal spray, its lead investigational product, for the management of PSVT, is under review at the U.S. Food and Drug ...

PDUFA date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT ...